Memphis Pharmaceuticals results, Q2 2026
Net profit, assets, equity and cash flow for Q2 2026, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit129 millionEGP · +1.2% vs the same period a year earlier
Shareholders' equity710 millionEGP · +85.7% vs the same period a year earlier
In short
- Memphis Pharmaceuticals's net profit for Q2 2026 was about 129 million EGP, up +1.2% from 127 million EGP in Q2 2025.
Key lines against the same period a year earlier
This periodQ2 2025Change
Net profit129 million127 million+1.2%
Gross profit386 million268 million+44.3%
Total assets—1.34 billion—
Total liabilities———
Shareholders' equity710 million382 million+85.7%
Total liabilities and equity1.58 billion1.34 billion+17.5%
Operating cash flow—-29.02 million—
Investing cash flow—21.63 million—
Financing cash flow—-50.97 million—
Net change in cash———
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Memphis Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy